


PRODUCT: JNJ-7706621**ALTERNATE NAMES:** 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide**CATALOG NUMBER:** B1941-1, 5**AMOUNT:** 1 mg, 5 mg**STRUCTURE:****MOLECULAR FORMULA:** C₁₅H₁₂F₂N₆O₃S**MOLECULAR WEIGHT:** 394.36**CAS NUMBER:** 443797-96-4**APPEARANCE:** Crystalline solid**SOLUBILITY:** DMSO (>18 mg/ml)**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20 °C. Protect from air and light**DESCRIPTION:** JNJ-7706621 is a potent inhibitor of cyclin-dependent kinases (CDK) and Aurora kinases with IC₅₀ values of 9 nM, 4 nM, 11 nM and 15 nM for CDK1, 2 and Aurora A, B, respectively. In vitro assays shows that JNJ-7706621 inhibits glioblastoma cellular viability, proliferation, and migration via inducing glioblastoma cells apoptosis.**REFERENCES:** Zhong, S., *et al.* (2017). *World Neurosurg.* Oct 6. pii: S1878-8750(17)31692-3. doi: 10.1016/j.wneu.2017.09.176.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

AT-9823 (Cat. No. 2432-5, 25)
Aurora Kinase B Inhibitor (Cat. No. 1583-5, 25)
AZD1480 (Cat. No. 2315-1, 5)
CCT-129202 (Cat. No. B1934-5,25)
CCT-137690 (Cat. No. B1935-5,25)
CP-690550 (Cat. No. 1622-5, 25)
CYC-116 (Cat. No. B1936-5,25)
Danusertib (Cat. No. B1937-5,25)
ENMD-2076 (Cat. No. B1938-5,25)
GSK-1070916 (Cat. No. B1939-5,25)
Hesperadin (Cat. No. B1940-5,25)
JNJ-7706621 (Cat. No. B1941-5,25)
Lestaurtinib (Cat. No. 1805-500, 1000)
MLN8237 (Cat. No. 2718-5,25)
LLL12 (Cat. No. 1792-5, 25)
MS-1020 (Cat. No. 1911-1)
PF-03814735 (Cat. No. B1257-1,5)
Reversine (Cat. No. 1851-1, 5)
Ruxolitinib, free base (Cat. No. 2139-5, 25)
Tozasertib (Cat. No. 1595-25, 100)
EZSolution™ Tozasertib (Cat. No. 1803-
TC-S 7010 (Cat. No. B1203-5,25)
TG101348 (Cat. No. 2314-1, 5)
Tyrphostin AG 490 (Cat. No. 1570-5)
WHI-P131 (Cat. No. 1853-5, 25)
WP1066 (Cat. No. 1809-5, 25)

USAGE: **FOR RESEARCH USE ONLY! Not to be used in humans**